ConductScience.org, home

Paper313007

The beige mutation in the mouse selectively impairs natural killer cell function.

Roder J and 1 other. Nature, 1979. Cited by 448 papers, by iCite.

Cite this record

ConductScience Library. The beige mutation in the mouse selectively impairs natural killer cell function. Papers, record 313007. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/313007

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The beige mutation in the mouse selectively impairs natural killer cell function.
PubMed
Journal
Nature
PubMed
Year
1979
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
448
iCite
Relative citation ratio, by iCite
10.8
iCite
Revised in PubMed
2019-06-17
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Roder JJ
2Duwe AA

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Cytotoxicity, ImmunologicMajor topic
Immunity, InnateMajor topic
Killer Cells, NaturalMajor topic
Mice, Mutant StrainsMajor topic
Animals
Antibody-Dependent Cell Cytotoxicity
Immunologic Memory
Macrophages
Mice
Spleen
T-Lymphocytes

Source PubMed

Download CSV of topics

Cited by126

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 448 citations.

PMIDTitleJournalYearIn PapersSource
39117835Murine Models of Familial Cytokine Storm Syndromes.Adv Exp Med Biol2024https://conductscience.org/library/papers/39117835PubMed
38544830Animal model considerations for chordoma research: reproducing the tumor microenvironment in vivo with humanized mice.Front Oncol2024https://conductscience.org/library/papers/38544830PubMed
38390969Xenograft and organoid models in developing precision medicine for gastric cancer (Review).Int J Oncol2024https://conductscience.org/library/papers/38390969PubMed
37641405FAP-retargeted Ad5 enables in vivo gene delivery to stromal cells in the tumor microenvironment.Mol Ther2023https://conductscience.org/library/papers/37641405PubMed
37344821Generation, evolution, interfering factors, applications, and challenges of patient-derived xenograft models in immunodeficient mice.Cancer Cell Int2023https://conductscience.org/library/papers/37344821PubMed
34837653The lysosomal trafficking regulator is necessary for normal wound healing.Wound Repair Regen2022https://conductscience.org/library/papers/34837653PubMed
33498509Comparison of Genetically Engineered Immunodeficient Animal Models for Nonclinical Testing of Stem Cell Therapies.Pharmaceutics2021https://conductscience.org/library/papers/33498509PubMed
31959757Distinctive phenotypes and functions of innate lymphoid cells in human decidua during early pregnancy.Nat Commun2020https://conductscience.org/library/papers/31959757PubMed
31412684Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (PDX) Models.Cells2019https://conductscience.org/library/papers/31412684PubMed
30455698Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.Front Immunol2018https://conductscience.org/library/papers/30455698PubMed
29654211Efficacy and Mechanism of Antitumor Activity of an Antibody Targeting Transferrin Receptor 1 in Mouse Models of Human Multiple Myeloma.J Immunol2018https://conductscience.org/library/papers/29654211PubMed
29654064Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab.Mol Cancer Ther2018https://conductscience.org/library/papers/29654064PubMed
28025748Patient-derived xenograft (PDX) models in basic and translational breast cancer research.Cancer Metastasis Rev2016https://conductscience.org/library/papers/28025748PubMed
27835880Targeted depletion of PIK3R2 induces regression of lung squamous cell carcinoma.Oncotarget2016https://conductscience.org/library/papers/27835880PubMed
27199990Licensed and Unlicensed NK Cells: Differential Roles in Cancer and Viral Control.Front Immunol2016https://conductscience.org/library/papers/27199990PubMed
25941352Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma.Cancer Immunol Res2015https://conductscience.org/library/papers/25941352PubMed
23856999Ischemia-reperfusion injury accelerates human antibody-mediated transplant vasculopathy.Transplantation2013https://conductscience.org/library/papers/23856999PubMed
22919660Natural killer cells in experimental and human leishmaniasis.Front Cell Infect Microbiol2012https://conductscience.org/library/papers/22919660PubMed
21407206Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer.Nat Commun2011https://conductscience.org/library/papers/21407206PubMed
20939894Natural killer cells are crucial for the efficacy of Icon (factor VII/human IgG1 Fc) immunotherapy in human tongue cancer.BMC Immunol2010https://conductscience.org/library/papers/20939894PubMed

See all 126 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/313007

GET https://conductscience.org/api/papers/v1/313007/cited_by?page=2